It is not known whether Omvoh (mirikizumab-mrkz) is safe to receive while pregnant or breastfeeding. Certain factors, including the risks of not treating your condition during pregnancy may ...
Omvoh is the first IL-23p19 antagonist to demonstrate multi-year, sustained efficacy and safety for both Crohn's disease and ulcerative colitis INDIANAPOLIS, Feb. 7, 2025 /PRNewswire/ -- Eli ...
Eli Lilly and Company announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to severely active Crohn's disease receiving two years of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback